Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group.
Ms. Zaim will lead Eisai's Neurology Commercial Development team in creating and driving commercial strategies for pipeline assets and late stage compounds approaching the commercialization stage. As the Global Lead for Alzheimer's Disease (AD), she will develop strategies and head the collaborative efforts of internal and external stakeholders to progress the development of existing as well as potential future AD assets. In addition to her functional responsibilities, she has been appointed as a standing member of the Executive Committee for the Neurology Business Group.
"With her deep expertise in the commercial development of in-line and pipeline compounds, and extensive knowledge of Alzheimer's disease and other neurodegenerative disease states, Beyhan is a tremendous addition to Eisai," said Ivan Cheung, Chairman and CEO of Eisai Inc. and President of the Neurology Business Group. "We are confident that she will help drive the global growth of Eisai's products, as well as work to ensure that Eisai remains a leader in the AD marketplace."
Ms. Zaim joins Eisai from Pfizer, where she held diverse global positions encompassing business development, global marketing, strategic planning, and all aspects of commercial development. She also held a number of international assignments, including Asia Business Development Director based in Hong Kong and Country Manager of Thailand. In her most recent roles, she served as Vice President of External Opportunities and New Business; Vice President of Commercial Development Primary Care Business Unit; and Vice President, Medicine Team Leader.
Ms. Zaim holds a Master of Business Administration from Columbia Business School, the business school of Columbia University located in Manhattan, New York City. She earned her Bachelor of Science degree from the Rutgers School of Pharmacy.